NYSE - Nasdaq Real Time Price USD

Becton, Dickinson and Company (BDX)

175.41
+3.14
+(1.82%)
At close: May 16 at 4:00:02 PM EDT
174.50
-0.91
(-0.52%)
After hours: May 16 at 7:57:12 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Thomas E. Polen Jr. President, CEO & Chairman 3.73M -- 1973
Mr. Christopher J. DelOrefice CPA Executive VP & CFO 1.78M -- 1972
Ms. Shana Carol Neal Executive VP & Chief People Officer 1.39M -- 1966
Mr. Michael Garrison Executive VP & President of Medical segment 1.33M -- 1970
Mr. Richard Byrd Executive VP & President of Interventional Segment 1.37M -- 1968
Ms. Pamela L. Spikner Senior VP, Chief Accounting Officer & Controller -- -- 1978
Ms. Elizabeth McCombs Executive VP & Chief Technology Officer -- -- 1977
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D. Senior VP & Chief Scientific Officer -- -- --
Ms. Denise Russell Fleming Executive VP of Technology & Global Services and Chief Information Officer -- -- 1971
Mr. Greg Rodetis Senior VP, Treasurer & Head of Investor Relations -- -- --

Becton, Dickinson and Company

1 Becton Drive
Franklin Lakes, NJ 07417-1880
United States
201 847 6800 https://www.bd.com
Sector: 
Healthcare
Full Time Employees: 
70,000

Description

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation systems, and medication inventory optimization and tracking systems; hemodynamic monitoring systems; and prefillable drug delivery systems. The BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Corporate Governance

Becton, Dickinson and Company’s ISS Governance QualityScore as of May 1, 2025 is 3. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 1; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

June 9, 2025 at 12:00 AM UTC

Ex-Dividend Date

June 30, 2025 at 12:00 AM UTC

Dividend Date

August 7, 2025 at 12:30 PM UTC

Becton, Dickinson and Company Earnings Date

Recent Events

May 2, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 1, 2025 at 12:00 AM UTC

10-Q: Periodic Financial Reports

March 27, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

February 6, 2025 at 12:00 AM UTC

10-Q: Periodic Financial Reports

February 5, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 31, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

January 10, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

December 19, 2024 at 12:00 AM UTC

DEFA14A: Proxy Statements

November 27, 2024 at 12:00 AM UTC

10-K: Periodic Financial Reports

November 7, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

Related Tickers